Browse articles from EyeWorld.org related to conjunctivitis. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
While this bonus issue delves into the diverse aspects of dry eye, the EyeWorld Editorial Board thought it was important to call out dry eye masqueraders—conditions that might initially seem like dry eye but aren’t. EyeWorld spoke with one physician to gain insights on these dry eye decoys.
➤ ASCRS advocacy helps protect MIGS coverage ➤ FDA approves generic loteprednol etabonate ophthalmic suspension ➤ Orphan Drug Designation granted for corneal endothelial cell substitute ➤ Positive results in Phase 2 clinical trial for contact lens discomfort ➤ First patient visits ➤ Acquisition news ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ FDA expands eye drop warning list ➤ Positive results in Phase 2a trial for new biodegradable sustained drug delivery implant ➤ Phase 2b study begins for investigational therapy for acute infectious conjunctivitis ➤ FDA approves additional treatment indication for bispecific antibody ➤ Enrollment complete for study evaluating femtosecond laser-created trabeculotomy ➤ Company to study personalized medicine for patients with wet AMD ➤ Enrollment complete for Phase 2b trial evaluating wet AMD therapy ➤ Pivotal trial for wet AMD therapy begins ➤ Survey evaluates female ophthalmologist experiences ➤ ASCRS news and events
➤ Positive topline results in Phase 3 clinical trial for allergic conjunctivitis treatment ➤ Phase 1b topline data on investigational dry eye drop ➤ First patients dosed in Phase 1b/2 trial for Wnt agonist antibody ➤ Study: U.S. prevalence of diabetic retinopathy ➤ ASCRS news and events
➤ FDA approves first bispecific antibody for the eye ➤ FDA approves treatment for rare uveal melanoma ➤ New data on clinical programs investigating phentolamine ophthalmic solution ➤ Phase 2 clinical trial results published for investigational drug targeting allergic conjunctivitis ➤ Patient dosing begins for gene therapy to treat X-linked retinitis pigmentosa ➤ New effort to research glaucoma ➤ ASCRS news and events
➤ FDA approves drops for vernal keratoconjunctivitis ➤ Data from investigational first-in-class dry eye therapy ➤ FDA accepts BLA for Port Delivery System of ranibizumab ➤ Companies enter collaboration to investigate treatments for dry AMD ➤ ASCRS news and events
➤ Survey: 96% of ophthalmologists vaccinated against COVID-19 ➤ Phase 2b/3 results from trial for Demodex blepharitis ➤ Data from ongoing Phase 2a study of therapy for geographic atrophy ➤ First patient enrolled in Phase 2 study of nasal spray for neurotrophic keratopathy ➤ Next ASCRS Journal Club on July 8
➤ FDA grants De Novo authorization for new intense pulsed light device ➤ Post-approval study requirements fulfilled for clear corneal incision sealant ➤ Interim analysis for acute adenoviral conjunctivitis drug ➤ NDA resubmission for injection to treat macular edema associated with uveitis ➤ FDA approves abbreviated NDA for glaucoma drug ➤ Study: Functional and psychosocial impact of Demodex blepharitis ➤ Next ASCRS Journal Club on May 13
The right questions can be key to the early and correct diagnosis of various types of conjunctivitis.
Hyperacute bacterial conjunctivitis requires prompt diagnosis and treatments because in some cases, the organisms at fault could cause a life-threatening secondary condition.